Nxera Pharma Co (Nxera Pharma Co) 3-Year Revenue Growth Rate : 11.70% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co 3-Year Revenue Growth Rate?

Nxera Pharma Co's Revenue per Share for the three months ended in Dec. 2023 was $0.61.

During the past 12 months, Nxera Pharma Co's average Revenue per Share Growth Rate was -17.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Nxera Pharma Co was 87.40% per year. The lowest was -36.20% per year. And the median was 14.35% per year.

Competitive Comparison of Nxera Pharma Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Nxera Pharma Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's 3-Year Revenue Growth Rate falls into.

Nxera Pharma Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Nxera Pharma Co (OTCPK:SOLTF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Nxera Pharma Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.